Search clinical trials for: OPC-41061 7.5mg

Total 1331 results

Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema

Cirrhosis

Japan
Jiangsu Nhwa Pharmaceutical Co., Ltd.

Recruiting

A Single Ascending Dose Study Of CY150112 After Single Oral Administration in Healthy Chinese Subjects

Schizophrenia

China
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (TEMPO3:4)

Polycystic Kidney Disease, Autosomal Dominant

United States, Belgium, United Kingdom, Russian Federation, France, Australia, Netherlands, Italy, Japan, Denmark, Romania, Poland, Canada, Argentina, Germany
Green Cross Corporation
C&R Research, Inc.; CRScube

Unknown

Phase II Study to Evaluate the Efficacy and Safety of GC6101A in Subjects With Gastritis

Gastritis

Korea, Republic of
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia (SALACIA)

Hyponatremia | Inappropriate ADH Syndrome | Dilutional Hyponatremia

United States
Bayer

Completed

Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets

Heart Failure

Germany
Otsuka Pharmaceutical Development & Commercialization...

Completed

Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease

Netherlands
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]

Autosomal Dominant Polycystic Kidney Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg

Cirrhosis

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Open-label Dose-finding Trial of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis

Chronic Renal Failure

Japan
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Autosomal Recessive Polycystic Kidney Disease (ARPKD)

United States, Belgium, Spain, Germany, United Kingdom, Poland
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]

Autosomal Dominant Polycystic Kidney Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study of OPC-41061 Orally Disintegrating (OD) Tablets Using 2 Different Formulations and 2 Dosing Regimens in Healthy Adult Male Subjects

Healthy Adult Male

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Multicenter, Open-label, Dose-finding Trial of OPC-41061 to Investigate Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety in Patients With Carcinomatous Edema (Phase 2)

Carcinomatous Edema

Japan
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (TEMPO 2:4)

Polycystic Kidney, Autosomal Dominant

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Tolvaptan Extension Study in Participants With ADPKD (TEMPO 4/4)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States, Australia, Belgium, Germany, Italy, Poland, Romania, United Kingdom, Argentina, Canada, France, Netherlands, Russian Federation
Otsuka Pharmaceutical Development & Commercialization...

Completed

Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

Polycystic Kidney, Autosomal Dominant

Belgium, Germany, Italy, Spain, Sweden, United States, Canada, Australia, Netherlands, Czechia, Poland, Denmark, Israel, Hungary, Russian Federation, South Africa, United Kingdom, Romania, Argentina, Norway
Otsuka Pharmaceutical Co., Ltd.

Completed

A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)

Edema, Cardiac

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration

Chronic Renal Failure

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)

Cardiac Edema

Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

Chronic Kidney Disease | Autosomal Dominant Polycystic Kidney Disease

Australia, Belgium, Italy, Spain, Sweden, United States, Canada, Netherlands, Czechia, Poland, Germany, Russian Federation, Hungary, Israel, Puerto Rico, Argentina, Denmark, South Africa, United Kingdom, Norway, France, Romania
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema

Cirrhosis

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema

Cirrhosis

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)

Cardiac Edema

Japan
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients (INSIGHT)

Hyponatremia

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD

Autosomal Dominant Polycystic Kidney Disease

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)

Edema | Heart Failure, Congestive

Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Germany, Italy, Belgium, United Kingdom
Otsuka Pharmaceutical Co., Ltd.

Completed

A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration

Chronic Renal Failure

Japan
Beijing Friendship Hospital
Chinese University of Hong Kong

Completed

Efficacy and Safety of Tolvaptan in Cirrhotic Patients With Hyponatremia (OASIS)

Liver Cirrhosis | Hyponatremia

China
Otsuka Pharmaceutical Development & Commercialization...

Completed

8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (NOCTURNE)

Autosomal Dominant Polycystic Kidney Disease

United States
Otsuka Pharmaceutical Co., Ltd.

Recruiting

A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])

Cardiac Edema (CHF)

Japan
Eye & ENT Hospital of Fudan University

Recruiting

An Observational Study of Clinical Treatments for Patients With Oropharyngeal Carcinoma

Oropharynx Carcinoma

China
Kyowa Kirin Co., Ltd.

Completed

A Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes Type 2

Japan
Otsuka Pharmaceutical Co., Ltd.

Recruiting

Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma (MM)

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-term Trial of OPC-34712 in Patients With Schizophrenia

Schizophrenia

Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

Multicenter, Open-label, Safety and Tolerability Study (STEP 210)

Schizophrenia

United States, Bulgaria, Philippines, Romania, Russian Federation, Serbia, Croatia, India, Korea, Republic of, Slovakia, Taiwan, Ukraine
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia (ZENITH)

Schizophrenia

Korea, Republic of, United States, Philippines, Malaysia, Croatia, Serbia, Russian Federation, Ukraine, Romania, Puerto Rico, Colombia, Turkey, Poland, Taiwan, Canada, Latvia, Slovakia, Mexico, Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects

Schizophrenia | Psychiatric Disorders

United States
Kyowa Kirin Co., Ltd.

Completed

Along-term Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes, Type 2

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of OPC-262 in Patients With Type 2 Diabetes

Type 2 Diabetes

Japan
Otsuka Pharmaceutical Co., Ltd.

Terminated

A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis

Colitis, Ulcerative

Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects

Schizophrenia

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis

Pain Due to Osteoporosis

Japan
Kyowa Kirin Co., Ltd.

Completed

A Phase 3 Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes, Type 2

Japan
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712

Schizophrenia
Otsuka Pharmaceutical Development & Commercialization...
Bill and Melinda Gates Foundation

Completed

A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis

Pulmonary TB

South Africa
Otsuka Beijing Research Institute

Completed

OPC-61815 in Healthy Chinese Male Subjects

Healthy Adult Male

China
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870

Epilepsy

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia (BEACON)

Acute Schizophrenia

United States, Philippines, Taiwan, Russian Federation, Croatia, Colombia, Mexico, Slovakia

Search clinical trials for: OPC-41061 7.5mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations